Cannabis Science and Technology magazine is seeking contributed manuscripts for the November 2018 and January 2019 issues.
As more states legalize cannabis, increasingly stringent testing requirements are being developed on the state level for pesticide and mycotoxin levels in cannabis products.
The FDA released a statement this week about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum.
George Anastassov, the CEO of AXIM Biotech, recently spoke to us about the current good manufacturing methods (cGMPs) his company has developed, their significance to the market, and plans for the future.
The U.S. Food and Drug Administration (FDA) recently approved the drug Epidiolex, which contains cannabidiol (CBD), as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy—Lennox-Gastaut syndrome and Dravet syndrome—in patients two years of age and older (1).
EVIO Labs Florida (Broward County, Florida) was recently recognized for their participation in The Emerald Test (Emerald Scientific), which is an interlaboratory comparison and proficiency assessment for cannabis testing.
The 2018 Cannabis Science Conference will be held August 27–29, in Portland, Oregon.
Cannabis strains may have just been given the fast track to a pharmaceutical version (pill form) that captures the entire strain specific effects through the use of a device termed the lossless activation chamber Y (LACY).
Thomas Jefferson University Announces Initiative to Study Health Outcomes in Medical Cannabis Patients
On Monday, May 14, 2018, Pennsylvania became the first state to add opioid addiction to its list of approved conditions for medicinal cannabis.